Curiosity Weekly – "Medicinal Psychedelics: Hype or Health?"

Date: March 25, 2026
Host: Dr. Samantha Yamin (aka Science Sam)
Guest: Dr. Ishrat Hussain, Psychiatrist & Senior Scientist (University of Toronto, CAMH)

Episode Overview

This episode of Curiosity Weekly addresses the growing interest and debate surrounding medicinal psychedelics. Host Dr. Samantha Yamin interviews Dr. Ishrat Hussain, a leading researcher, to separate scientific reality from hype and misinformation. Together, they cover the state of clinical research, the promise and limitations of psychedelic therapy for mental illnesses (like depression and PTSD), safety concerns, longstanding stigmas, and the importance of respecting Indigenous knowledge.

Key Discussion Points & Insights

1. Defining Psychedelics

• What are psychedelics?
  • The term "psychedelic" is not an official drug class but a descriptor for substances with strong psychological effects, mainly acting on the serotonin 2A receptor.
  • Quote:

    "It's a term that was developed in the mid 20th century and its origins stem from ancient Greek, so psyche meaning mind and delic meaning manifesting."
    (Dr. Ishrat Hussain, 08:17)

• Classic Psychedelics: LSD (synthetic), psilocybin (magic mushrooms), mescaline (peyote cactus), DMT (ayahuasca). All share similar serotonin receptor action.

2. Clinical Promise and Mechanisms

• Why consider them for mental health?
  • Early interest stemmed from lack of treatments for depression, anxiety, addictions aside from psychotherapy in mid-1900s.
  • Modern rationale: these treatments combine powerful biological, psychological, and social effects—psychedelics are given with therapy, potentially leading to profound and lasting change.
  • Quote:

    "Mental health conditions like depression, anxiety, PTSD, they're a combination of biological, psychological, social factors... psychedelic therapies are quite powerful for treating these types of conditions."
    (Dr. Ishrat Hussain, 11:53)

3. How Clinical Use Differs from Recreation

• Clinical trials use pharmaceutical-grade compounds with controlled dosages (e.g., psilocybin in capsules), not variable plant materials.
• Therapy occurs in safe, supportive environments with monitoring and preparatory sessions.
  • Quote:

    "It's very different from taking it recreationally."
    (Dr. Ishrat Hussain, 13:14)

4. Current Clinical Evidence

• Psilocybin for Depression:
  • Leading candidate for treatment-resistant depression.
  • Multiple small and now large-scale (500+ person) phase III trials show significant improvements when combined with therapy.
• Other Trials:
  • MDMA (not a classic psychedelic, but administered similarly) shows promise for PTSD.
  • LSD is being studied for generalized anxiety.
  • Quote:

    "Now we've recently completed the largest phase three clinical trial... psilocybin when combined with psychological support showed to improve symptoms of depression, treatment resistant depression."
    (Dr. Ishrat Hussain, 14:46)

• Effect Duration:
  • About a third maintain improvements up to a year after treatment; the rest may need repeat dosing. More long-term data is in progress.
  • Quote:

    "About a third of people over the course of a year don't need further treatments. However, there are 2/3 that seem to require additional treatments."
    (Dr. Ishrat Hussain, 16:41)

5. Microdosing: Placebo or Powerful?

• Popularized via internet subculture for general life optimization.
• Clinical data is weak—well-controlled trials in patient populations are lacking.
• Studies in recreational users show microdosing generally not better than placebo; perceived benefits likely due to expectancy.
  • Quote:

    "It's shown that microdosing psychedelics isn't really better than a placebo. So it seems that there is a sort of expectation or placebo effect..."
    (Dr. Ishrat Hussain, 18:51)

6. Safety Considerations

• Large-scale real-world databases indicate good tolerability, except when combined with substances (alcohol/cannabis) or in those with pre-existing medical or psychiatric conditions.
• Safety in clinical populations (especially vulnerable, e.g., bipolar, psychosis) still uncertain and under investigation.
• Family/personal history of psychotic disorders is a contraindication; age groups outside adults understudied.
• Quote:

  "For anybody that has a personal or family history of a serious mental illness, I would say that they're not safe..."
  (Dr. Ishrat Hussain, 21:01)

7. Regulatory and Research Challenges

• The FDA’s 2024 rejection of MDMA-assisted therapy for PTSD was due largely to trial methodology and inability to regulate the psychotherapeutic (therapy) aspect, not the drug alone.
  • Quote:

    "The FDA does not have jurisdiction over psychotherapy. And the outcome was that we have to characterize the role of the psychotherapy in this treatment."
    (Dr. Ishrat Hussain, 22:27)

• Dr. Hussain’s group is now studying drug-plus-therapy vs. drug-alone treatments in large, controlled trials.

8. Addressing Stigma

• Public discussion—documentaries, media coverage—have lessened stigma around psychedelics, but cultural resistance remains, especially regarding using historically “street drugs” as therapies.
• Overhype is also a problem: Unrealistic expectation management is a major task for clinicians.
• Quote:

  "A lot of the public discourse around it has in fact led to what you referred to earlier, a lot of hype... people come in thinking that this treatment... is gonna transform their lives and cure them... that's simply not the case."
  (Dr. Ishrat Hussain, 24:04)

9. Respecting Indigenous Knowledge

• Many medicinal psychedelics have roots in indigenous healing practices.
• Researchers now strive to include Indigenous voices in their work and respect these medicines' origins.
  • Quote:

    "Some of these medicines... came to use in Western medicine because of their centuries long use in spiritual shamanic ceremonies that were used for healing in those communities. So there's immense value in that and we're trying to do our best to be as respectful to that as we can."
    (Dr. Ishrat Hussain, 25:38)

Notable Quotes & Memorable Moments

• On Clinical Setting:

  "It is a full day visit to the hospital or clinic... the doses that we are looking at... would cause quite powerful psychedelic effects..."
  (Dr. Ishrat Hussain, 18:01)

• Listener Questions:

  • Long-term effects:

    "We're actually looking and doing the work now in which we're following up people for a year in this large phase three study..."
    (Dr. Ishrat Hussain, 16:51)

  • Integration of Indigenous Wisdom:

    "...what we've tried to do as best as possible is to include people from the indigenous community into our research team."
    (Dr. Ishrat Hussain, 25:29)

Major Timestamps

• [08:17] – What is a psychedelic?
• [10:37] – Why use psychedelics for mental health conditions?
• [12:39] – Differences between clinical and recreational use
• [14:10] – State of research: Psilocybin for depression
• [16:32] – How long do psychedelic treatment effects last?
• [18:00] – Practical aspects: Dosage, session logistics, microdosing discussion
• [19:47] – Safety insights from large data analysis
• [22:14] – FDA concerns and future research directions
• [23:31] – Stigma and public expectations
• [25:13] – Indigenous knowledge and integration

Tone & Language

• Conversational, clear, and demystifying.
• Science-backed without overselling hope; candid about knowledge gaps.
• Emphasis on ethical, respectful medical research and community engagement.

Summary Takeaways

• Psychedelics—especially psilocybin and MDMA—show promising results for difficult-to-treat mental health conditions, but are neither miracle cures nor risk-free.
• Clinical use is highly controlled, distinct from recreational use. Long-term efficacy and safety for various populations need more data.
• Microdosing is likely more placebo than powerful.
• Addressing stigma, respecting indigenous origins, and tempering public hype are ongoing priorities for researchers and clinicians.

For anyone curious about the science, safety, and emerging potential of psychedelics in psychiatry, this episode gives a nuanced, up-to-date overview—dispelling the myths while spotlighting where research is headed next.